SCHEMBL6320995

SCHEMBL6320995

Cc1nc(C)n(-c2ccc([N+](=O)[O-])cc2)n1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.67
LMNA P02545 4/20 0.62
HTT P42858 3/20 0.59
L3MBTL1 Q9Y468 1/20 0.59
MAPT P10636 7/20 0.58
KMT2A Q03164 3/20 0.58
MEN1 O00255 2/20 0.58
ALDH1A1 P00352 5/20 0.55
POLB P06746 2/20 0.55
NPC1 O15118 3/20 0.51
RAB9A P51151 3/20 0.51
KDM4E B2RXH2 1/20 0.49
SMN1; SMN2 Q16637 3/20 0.48
NFKB1 P19838 2/20 0.48
NFKB2 Q00653 2/20 0.48
RELA Q04206 2/20 0.48
ACHE P22303 1/20 0.46
HSD17B10 Q99714 1/20 0.46
PKM P14618 1/20 0.46
PTGS2 P35354 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9768625 0.89 MAPT (0.79) TDP1LMNAHTTL3MBTL1MAPT
SCHEMBL11073261 0.84 TDP1 (0.63) TDP1LMNAHTTL3MBTL1MAPT
SCHEMBL11065466 0.81 TDP1 (0.60) TDP1LMNAHTTL3MBTL1MAPT
SCHEMBL1820467 0.80 TDP1 (1.00) TDP1LMNAHTTL3MBTL1MAPT
SCHEMBL4549451 0.79 MAPT (0.58) TDP1LMNAHTTL3MBTL1MAPT
SCHEMBL1822332 0.77 TDP1 (0.74) TDP1LMNAHTTL3MBTL1MAPT
SCHEMBL3242008 0.77 LMNA (1.00) TDP1LMNAHTTL3MBTL1MAPT
SCHEMBL24359770 0.76 PDE10A (0.42) TDP1LMNAHTTL3MBTL1MAPT
SCHEMBL6884461 0.76 PTGS2 (0.66) TDP1MAPTKMT2AMEN1POLB
SCHEMBL1187206 0.73 PKM (0.64) TDP1LMNAHTTL3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6941051-B2 Method for producing non-linear optical organic crystal film REVEO, INC. (US) 2005-09-06 US claimed
US-20040033038-A1 Method for producing non-linear optical organic crystal film XU JIANJUN (US) 2004-02-19 US claimed
CN-1459047-A Method for producing non-linear optical organic crystal film REVEO INC (US) 2003-11-26 CN claimed
US-6577798-B2 Method for producing non-linear optical organic crystal film REVEO, INC. 2003-06-10 US claimed
US-20020041427-A1 Method for producing non-linear optical organic crystal film REVEO, INC. 2002-04-11 US claimed
WO-2002008828-A2 COMPOSITE NONLINEAR OPTICAL FILM, METHOD OF PRODUCING THE SAME AND APPLICATIONS OF THE SAME REVEO, INC. (US) 2002-01-31 WO claimed
WO-2002006890-A2 METHOD FOR PRODUCING NON-LINEAR OPTICAL ORGANIC CRYSTAL FILM REVEO, INC. (US) 2002-01-24 WO claimed
US-6303056-B1 Composite nonlinear optical film, method of producing the same and applications of the same REVEO, INC. 2001-10-16 US claimed
EP-0418916-B1 Optical wavelength converting method FUJI PHOTO FILM CO LTD (JP) 1995-08-09 EP claimed
US-5080507-A OPTICAL WAVELENGTH CONVERTING METHOD FUJI PHOTO FILM CO., LTD. (JP) 1992-01-14 US claimed
EP-0418916-A2 Optical wavelength converting method Fuji Photo Film Co., Ltd. (JP) 1991-03-27 EP claimed
JP-4157429-A None JP disclosed
JP-4157430-A None JP disclosed
EP-3564232-B1 BMP-SIGNAL-INHIBITING COMPOUND RIKEN (JP) 2022-01-26 EP disclosed
US-10954216-B2 BMP-signal-inhibiting compound RIKEN (JP) 2021-03-23 US disclosed
US-4952013-A Optical wavelength converter device FUJI PHOTO FILM CO., LTD. (JP) 1990-08-28 US disclosed
US-4909596-A Optical wavelength converter module FUJI PHOTO FILM CO., LTD. (JP) 1990-03-20 US disclosed
US-4909596-A Optical wavelength converter module FUJI PHOTO FILM CO., LTD. (JP) 1990-03-20 US disclosed
EP-0334363-A2 Optical wavelength converter device Fuji Photo Film Co., Ltd. (JP) 1989-09-27 EP disclosed
US-4830447-A Optical wavelength conversion device FUJI PHOTO FILM CO., LTD. (JP) 1989-05-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10954216-B2 BMP-signal-inhibiting compound BMP1, BMP2, BMP4 TDP1 4110/4885LMNA 1065/4885HTT 4828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.